Citation: Luqing Zhao, Dan Dou, Di Zhang, Shuqing Wang, Xihan Zhu, Ning Ding, Shengsheng Zhang, Chao Li. Nanotechnology-based natural remedies: Advancing inflammatory bowel disease treatment through targeted drug delivery[J]. Chinese Chemical Letters, ;2026, 37(5): 111262. doi: 10.1016/j.cclet.2025.111262 shu

Nanotechnology-based natural remedies: Advancing inflammatory bowel disease treatment through targeted drug delivery

Luqing Zhao ^{a, 1} ,
Dan Dou ^{a, 1} ,
Di Zhang ^b ,
Shuqing Wang ^c ,
Xihan Zhu ^a ,
Ning Ding ^a ,
Shengsheng Zhang ^{a, *,} ,
Chao Li ^{b, *,}

a.
Digestive Disease Center, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China
b.
State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, China
c.
Beijing University of Chinese Medicine, Beijing 100029, China

zhangshengsheng@bjzhongyi.com

lichao@mail.buct.edu.cn

Received Date: 25 November 2024
Revised Date: 23 April 2025
Accepted Date: 26 April 2025
Available Online: 27 April 2025

Figures(2)

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, represents a significant health challenge due to its intricate interplay of genetic, environmental, and immunological factors. While current treatments are effective at managing symptoms, they are not without drawbacks, such as potential side effects, the financial strain on patients, and the risk of complications. Nanotechnology presents an innovative solution to these challenges, offering the potential to improve the bioavailability, stability, and precise delivery of natural compounds with potent anti-inflammatory properties. This review examines the array of nanoparticle (NP) delivery systems that are revolutionizing IBD treatment, including lipid-based NPs, polymeric NPs, metallic NPs, plant-derived exosomes, and mesoporous silica NPs. Furthermore, the review explores the various responsive mechanisms of NPs, including pH-responsive, reactive oxygen species (ROS)-responsive, enzyme-responsive, charge-mediated, ligand-receptor targeted, and multi-responsive systems. The therapeutic potential of nanomedicines derived from natural products is highlighted, with a focus on their roles in immunomodulation, reducing inflammation, repairing the intestinal barrier, and modulating the gut microbiota. Nanotechnology boosts IBD treatment with novel natural NPs. NPs delivery systems offer notable benefits, such as improving drug solubility, increasing the efficiency of absorption, alongside providing a controlled and sustained release of therapeutic agents directly at the inflammation site. Despite the promising capabilities of nanotechnology in IBD treatment, obstacles remain. These include the necessity for comprehensive toxicological assessments, formulating strategies to guarantee the safety and effectiveness of these innovative treatments. Therefore, this review provides a systematic analysis that provides guidance for the research and development of NPs based natural products.
- Inflammatory bowel disease,
- Natural product nanomaterials,
- Colon targeting,
- Drug delivery system,
- Therapeutic mechanisms
1. [1]
  GBD 2017 Inflammatory Bowel Disease Collaborators, Lancet Gastroenterol. Hepatol. 5 (2020) 17–30. doi: 10.1016/S2468-1253(19)30333-4
2. [2]
  C. Le Berre, S. Honap, L. Peyrin-Biroulet, Lancet 402 (2023) 571–584. doi: 10.1016/S0140-6736(23)00966-2
3. [3]
  D.J. Newman, Natl. Sci. Rev. 9 (2022) nwac206. doi: 10.1093/nsr/nwac206
4. [4]
  Z. Wen, L. Kang, H. Fu, et al., Carbohydr. Polym. 314 (2023) 120887. doi: 10.1016/j.carbpol.2023.120887
5. [5]
  L. Yin, X. Jiang, M. Wang, et al., Chin. Chem. Lett. 36 (2025) 110224. doi: 10.1016/j.cclet.2024.110224
6. [6]
  E.P. Stater, A.Y. Sonay, C. Hart, et al., Nat. Nanotechnol. 16 (2021) 1180–1194. doi: 10.1038/s41565-021-01017-9
7. [7]
  M. Sun, W. Ban, H. Ling, et al., Chin. Chem. Lett. 33 (2022) 4449–4460. doi: 10.1016/j.cclet.2022.03.061
8. [8]
  Y. Zhang, T. Wang, M. Sun, et al., Adv. Healthc. Mater. 12 (2023) e2300069. doi: 10.1002/adhm.202300069
9. [9]
  N. Li, M. Wang, Z. Lyu, et al., Front. Pharmacol. 14 (2023) 1158945. doi: 10.3389/fphar.2023.1158945
10. [10]
  Y. Zhou, X. Feng, H. Xu, et al., J. Mat. Chem. B 11 (2023) 244–260. doi: 10.1039/d2tb01965e
11. [11]
  C.J. Wang, M.J. Byun, S.N. Kim, et al., J. Control. Release 345 (2022) 1–19.
12. [12]
  H. Hadji, K. Bouchemal, Adv. Drug Deliv. Rev. 181 (2022) 114101. doi: 10.1016/j.addr.2021.114101
13. [13]
  T. Zhang, G. Zhu, B. Lu, et al., Pharm. Nanotechnol. 5 (2017) 83–94. doi: 10.1117/12.2285907
14. [14]
  X. Zhang, Y. Ma, L. Ma, et al., Carbohydr. Polym. 223 (2019) 115126. doi: 10.1016/j.carbpol.2019.115126
15. [15]
  P.S. Zangabad, S. Mirkiani, S. Shahsavari, et al., Nanotechnol. Rev. 7 (2018) 95–122. doi: 10.1515/ntrev-2017-0154
16. [16]
  E. Arab-Tehrany, K. Elkhoury, G. Francius, et al., Int. J. Mol. Sci. 21 (2020) 7276. doi: 10.3390/ijms21197276
17. [17]
  S. Das, A. Chaudhury, AAPS PharmSciTech 12 (2011) 62–76. doi: 10.1208/s12249-010-9563-0
18. [18]
  S. Pandey, F. Shaikh, A. Gupta, et al., Adv. Pharm. Bull. 12 (2022) 17–33.
19. [19]
  R. Paliwal, S.R. Paliwal, R. Kenwat, et al., Expert Opin. Ther. Patents 30 (2020) 179–194. doi: 10.1080/13543776.2020.1720649
20. [20]
  M. Sharma, N. Gupta, S. Gupta, RSC Adv. 6 (2016) 76621–76631. doi: 10.1039/C6RA12841F
21. [21]
  M. Sharma, S. Sharma, J. Wadhwa, Artif. Cell. Nanomed. Biotechnol. 47 (2019) 45–55. doi: 10.1080/21691401.2018.1543191
22. [22]
  S. Seyyedi-Mansour, M. Carpena, P. Barciela, et al., Adv. Colloid. Interface Sci. 340 (2025) 103457. doi: 10.1016/j.cis.2025.103457
23. [23]
  N. Poonia, R. Kharb, V. Lather, et al., Future Sci. OA 2 (2016) FSO135. doi: 10.4155/fsoa-2016-0030
24. [24]
  J. Lertpairod, W. Tiyaboonchai, J. Pharm. Investig. 52 (2022) 387–396. doi: 10.1007/s40005-022-00572-0
25. [25]
  E.M. Pridgen, F. Alexis, O.C. Farokhzad, Expert Opin. Drug Deliv. 12 (2015) 1459–1473. doi: 10.1517/17425247.2015.1018175
26. [26]
  M. Zu, Y. Ma, B. Cannup, et al., Adv. Drug Deliv. Rev. 176 (2021) 113887. doi: 10.1016/j.addr.2021.113887
27. [27]
  J.A. Lee, B.G. Jung, T.H. Kim, et al., Vet. Immunol. Immunopathol. 161 (2014) 193–204. doi: 10.15870/jsers.2014.12.53.4.193
28. [28]
  Z. Feng, S. Peng, Z. Wu, et al., Int. J. Biol. Macromol. 182 (2021) 2024–2036. doi: 10.1016/j.ijbiomac.2021.05.200
29. [29]
  Y. Zhou, M. Yang, X. Yan, et al., ACS Appl. Mater. Interfaces 15 (2023) 36061–36075. doi: 10.1021/acsami.3c09342
30. [30]
  B.R. Rizeq, N.N. Younes, K. Rasool, et al., Int. J. Mol. Sci. 20 (2019) 5776. doi: 10.3390/ijms20225776
31. [31]
  S. Nalinbenjapun, C. Ovatlarnporn, J. Drug Deliv. Sci. Technol. 57 (2020) 101397. doi: 10.1016/j.jddst.2019.101397
32. [32]
  L. Sun, X. Nie, W. Lu, et al., AAPS PharmSciTech 23 (2022) 179. doi: 10.1097/dad.0000000000002077
33. [33]
  S.I. Khater, M.M. Lotfy, M.N. Alandiyjany, et al., Biomedicines 10 (2022) 1654. doi: 10.3390/biomedicines10071654
34. [34]
  S.A. Ozkan, A. Dedeoglu, B.N. Karadas, et al., Turk. J. Pharm. Sci. 16 (2019) 481–492. doi: 10.4274/tjps.galenos.2019.48751
35. [35]
  R.Z. Tang, Z.Z. Liu, S.S. Gu, et al., J. Mat. Chem. B 9 (2021) 1521–1535. doi: 10.1039/d0tb02737e
36. [36]
  Z. Li, G. Li, J. Xu, et al., Adv. Mater. 34 (2022) e2109178. doi: 10.1002/adma.202109178
37. [37]
  C. Li, S.R. Obireddy, W.F. Lai, Drug Deliv. 28 (2021) 1594–1602. doi: 10.1080/10717544.2021.1955042
38. [38]
  N. Yuniarsih, A.Y. Chaerunisaa, K.M. Elamin, et al., Int. J. Nanomed. 19 (2024) 2733–2754. doi: 10.2147/ijn.s442123
39. [39]
  S. Zhang, L. Kang, S. Hu, et al., Int. J. Biol. Macromol. 167 (2021) 1598–1612. doi: 10.1016/j.ijbiomac.2020.11.117
40. [40]
  F. Wang, H. Yao, X. Wu, et al., Chin. Chem. Lett. 35 (2024) 108821. doi: 10.1016/j.cclet.2023.108821
41. [41]
  B.J. Swartzwelter, F. Barbero, A. Verde, et al., Cells 9 (2020) 284. doi: 10.3390/cells9020284
42. [42]
  S. Tang, J. Zheng, Adv. Healthc. Mater. 7 (2018) e1701503. doi: 10.1002/adhm.201701503
43. [43]
  K. Niikura, T. Matsunaga, T. Suzuki, et al., ACS Nano 7 (2013) 3926–3938. doi: 10.1021/nn3057005
44. [44]
  R.A. Sperling, W.J. Parak, Philos. Trans. R. Soc. A: Math. Phys. Eng. Sci. 368 (2010) 1333–1383. doi: 10.1098/rsta.2009.0273
45. [45]
  D.R. Sakthi, A. Girigoswami, M. Siddharth, et al., Appl. Biochem. Biotechnol. 194 (2022) 4187–4219. doi: 10.1007/s12010-022-03963-z
46. [46]
  A.K. Rengan, A.B. Bukhari, A. Pradhan, et al., Nano Lett. 15 (2015) 842–848. doi: 10.1021/nl5045378
47. [47]
  R.M. Hussein, H. Saleh, Nanomedicine 13 (2018) 1657–1679. doi: 10.2217/nnm-2018-0009
48. [48]
  S.N. Barnaby, A. Lee, C.A. Mirkin, Proc. Natl. Acad. Sci. U. S. A. 111 (2014) 9739–9744. doi: 10.1073/pnas.1409431111
49. [49]
  M. Piotrowska, J.B. Krajewska, M. Talar, et al., J. Drug Deliv. Sci. Technol. 86 (2023) 104273.
50. [50]
  J.B. Krajewska, O. Dlugosz, M. Salaga, et al., Int. J. Pharm. 585 (2020) 119549. doi: 10.1016/j.ijpharm.2020.119549
51. [51]
  J. Mondal, S. Pillarisetti, V. Junnuthula, et al., J. Control. Release 353 (2023) 1127–1149.
52. [52]
  M.N. Huda, M. Nafiujjaman, I.G. Deaguero, et al., ACS Biomater. Sci. Eng. 7 (2021) 2106–2149. doi: 10.1021/acsbiomaterials.1c00217
53. [53]
  J. Li, T. Luo, D. Wang, et al., J. Adv. Res. 68 (2025) 63–74.
54. [54]
  C. Gao, Y. Zhou, Z. Chen, et al., Theranostics 12 (2022) 5596–5614. doi: 10.7150/thno.73650
55. [55]
  M.Z. Zhu, H.M. Xu, Y.J. Liang, et al., J. Nanobiotechnology 21 (2023) 309. doi: 10.1186/s12951-023-02065-0
56. [56]
  J. Kim, S. Zhang, Y. Zhu, et al., J. Ginseng Res. 47 (2023) 627–637. doi: 10.1016/j.jgr.2023.01.004
57. [57]
  H. Shirazi, M. Daneshpour, S. Kashanian, et al., Beilstein J. Nanotechnol. 6 (2015) 1677–1689. doi: 10.3762/bjnano.6.170
58. [58]
  Z. Li, Y. Zhang, N. Feng, Expert Opin. Drug Deliv. 16 (2019) 219–237. doi: 10.1080/17425247.2019.1575806
59. [59]
  D. Jiang, X. Xia, Z. He, et al., J. Ind. Eng. Chem. 123 (2023) 382–395. doi: 10.1016/j.jiec.2023.03.055
60. [60]
  H. Wang, Y. Zhou, Q. Sun, et al., Front. Bioeng. Biotechnol. 9 (2021) 630352.
61. [61]
  F. Chen, Q. Liu, Y. Xiong, et al., Int. J. Nanomed. 16 (2021) 4225–4237. doi: 10.2147/ijn.s310952
62. [62]
  C. Yang, D. Merlin, Int. J. Nanomed. 14 (2019) 8875–8889. doi: 10.2147/ijn.s210315
63. [63]
  C. Lautenschlager, C. Schmidt, D. Fischer, et al., Adv. Drug Deliv. Rev. 71 (2014) 58–76.
64. [64]
  E.M. Jacob, A. Borah, S.C. Pillai, et al., Polymers 13 (2021) 862. doi: 10.3390/polym13060862
65. [65]
  D. Gugulothu, A. Kulkarni, V. Patravale, et al., J. Pharm. Sci. 103 (2014) 687–696. doi: 10.1002/jps.23828
66. [66]
  G. Zhang, W. Han, P. Zhao, et al., Nanoscale 15 (2023) 1937–1946. doi: 10.1039/d2nr04968f
67. [67]
  F.A. Moura, K.Q. de Andrade, S.J. Dos, et al., Redox Biol. 6 (2015) 617–639.
68. [68]
  L. Zhao, X. Du, J. Tian, et al., Front. Pharmacol. 12 (2021) 644387.
69. [69]
  B.N. Rooban, V. Sasikala, D.V. Gayathri, et al., Chem. Biol. Interact. 196 (2012) 30–38.
70. [70]
  C. Tan, H. Fan, J. Ding, et al., Mater. Today Bio 14 (2022) 100246.
71. [71]
  X. Peng, S.E. Wilken, T.S. Lankiewicz, et al., Nat. Microbiol. 6 (2021) 499–511. doi: 10.1038/s41564-020-00861-0
72. [72]
  S. Li, M. Jin, Y. Wu, et al., Drug Deliv. 28 (2021) 1120–1131. doi: 10.1080/10717544.2021.1934189
73. [73]
  I. Castangia, A. Nacher, C. Caddeo, et al., Acta Biomater. 13 (2015) 216–227.
74. [74]
  R. Coco, L. Plapied, V. Pourcelle, et al., Int. J. Pharm. 440 (2013) 3–12.
75. [75]
  X. Zhang, Z. Yuan, J. Wu, et al., ACS Nano 17 (2023) 21116–21133. doi: 10.1021/acsnano.3c04819
76. [76]
  T.T. Jubeh, Y. Barenholz, A. Rubinstein, Pharm. Res. 21 (2004) 447–453.
77. [77]
  N. Ye, P. Zhao, S. Ayue, et al., Int. J. Biol. Macromol. 232 (2023) 123229.
78. [78]
  Z. Huang, J. Gan, L. Jia, et al., Biomaterials 48 (2015) 26–36.
79. [79]
  C. Wang, Z. Guo, J. Liang, et al., Front. Bioeng. Biotechnol. 10 (2022) 1025155.
80. [80]
  M. Naeem, W. Kim, J. Cao, et al., Colloid Surf. B: Biointerfaces 123 (2014) 271–278.
81. [81]
  W. Li, Y. Li, Z. Liu, et al., Biomaterials 185 (2018) 322–332.
82. [82]
  C. Abraham, R. Medzhitov, Gastroenterology 140 (2011) 1729–1737.
83. [83]
  A. Geremia, P. Biancheri, P. Allan, et al., Autoimmun. Rev. 13 (2014) 3–10.
84. [84]
  S. Zhang, R. Langer, G. Traverso, Nano Today 16 (2017) 82–96.
85. [85]
  L.M. Hegarty, G.R. Jones, C.C. Bain, Nat. Rev. Gastroenterol. Hepatol. 20 (2023) 538–553. doi: 10.1038/s41575-023-00769-0
86. [86]
  C. Danne, J. Skerniskyte, B. Marteyn, et al., Nat. Rev. Gastroenterol. Hepatol. 21 (2024) 184–197. doi: 10.1038/s41575-023-00871-3
87. [87]
  X. Han, R. Luo, S. Qi, et al., J. Nanobiotechnology 21 (2023) 321.
88. [88]
  J. Zhang, A. Ou, X. Tang, et al., J. Nanobiotechnology 20 (2022) 389. doi: 10.3390/toxins14060389
89. [89]
  P. Diez-Echave, A.J. Ruiz-Malagon, J.A. Molina-Tijeras, et al., Int. J. Pharm. 606 (2021) 120935.
90. [90]
  H. Wang, L. Wang, S. Guo, et al., ACS Appl. Mater. Interfaces 14 (2022) 26327–26337. doi: 10.1021/acsami.2c02295
91. [91]
  J. Liu, Y. Bai, Y. Li, et al., Ebiomedicine 107 (2024) 105301.
92. [92]
  T. Takiishi, C. Fenero, N. Camara, Tissue Barriers 5 (2017) e1373208. doi: 10.1080/21688370.2017.1373208
93. [93]
  S. Citi, Science 359 (2018) 1097–1098. doi: 10.1126/science.aat0835
94. [94]
  M. Schwarzfischer, G. Rogler, Metabolites 12 (2022) 223. doi: 10.3390/metabo12030223
95. [95]
  Q. Shen, Z. Huang, J. Yao, et al., J. Adv. Res. 37 (2022) 221–233.
96. [96]
  S. Qi, R. Luo, X. Han, et al., ACS Appl. Mater. Interfaces 14 (2022) 50692–50709. doi: 10.1021/acsami.2c17827
97. [97]
  C. Guo, J. He, X. Song, et al., Pharmacol. Res. 149 (2019) 104463.
98. [98]
  J. Feng, Y. Wang, Y. Lv, et al., Mol. Pharm. 19 (2022) 4157–4170. doi: 10.1021/acs.molpharmaceut.2c00550
99. [99]
  Z. Zeng, Z. Xie, G. Chen, et al., Food Funct. 13 (2022) 649–663. doi: 10.1039/d1fo02702f
100. [100]
  H. Han, L. Ke, W. Xu, et al., Food Funct. 14 (2023) 8420–8430. doi: 10.1039/d3fo00641g
101. [101]
  B. Yilmaz, P. Juillerat, O. Oyas, et al., Nat. Med. 25 (2019) 323–336. doi: 10.1038/s41591-018-0308-z
102. [102]
  M. Akhtar, Y. Chen, Z. Ma, et al., Anim. Nutr. 8 (2022) 350–360.
103. [103]
  Z. Zhang, H. Zhang, T. Chen, et al., Cell Commun. Signal. 20 (2022) 64.
104. [104]
  S. You, Y. Ma, B. Yan, et al., Front. Nutr. 9 (2022) 1000517.
105. [105]
  X. Bai, Z. Feng, S. Peng, et al., Biomater. Adv. 139 (2022) 213002.
106. [106]
  X. Li, Z. Duan, X. Chen, et al., Adv. Mater. 35 (2023) 2300548.
107. [107]
  Y. Zhang, Z. Fang, D. Pan, et al., Adv. Mater. 36 (2024) 2401304.
1. [1]
  Zeyu Li , Huan Shen , Wenli Cai , Quangang Xu , Wei Xia , Keke Ning , Ergang Liu , Yongzhuo Huang . Colon-targeted pellets encapsulating patchouli oil cocrystal for inflammatory bowel disease treatment. Chinese Chemical Letters, 2026, 37(5): 111292-. doi: 10.1016/j.cclet.2025.111292
2. [2]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
3. [3]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
4. [4]
  Mengmeng Miao , Yisheng Peng , Hui Liu , Hu Chen , Xu Cheng , Shangqing Chen , Kaifei Yan , Hongwei Cheng , Gang Liu . Micro-nanomaterials-engineered delivery systems for reshaping the tumor immune microenvironment in hepatocellular carcinoma. Chinese Chemical Letters, 2026, 37(5): 111390-. doi: 10.1016/j.cclet.2025.111390
5. [5]
  Jingting Wang , Yuanyuan Chen , Linlin Han , Shasha Xia , Xingyao Zhang , Peng Xue , Yuejun Kang , Jian Ming , Zhigang Xu . Microenvironment responsive pod-structured astaxanthin nanocarrier for ameliorating inflammatory bowel disease. Chinese Chemical Letters, 2024, 35(7): 109029-. doi: 10.1016/j.cclet.2023.109029
6. [6]
  Linzhou Yin , Xiaowen Jiang , Miao Wang , Yiren Yang , Zhonggui He , Jin Sun , Huiyuan Gao , Mengchi Sun . Phytoconstituent-derived nano-medicines/vesicles providing a promising dawn for inflammatory bowel disease. Chinese Chemical Letters, 2025, 36(6): 110224-. doi: 10.1016/j.cclet.2024.110224
7. [7]
  Yihao He , Ru Guo , Lu Yang , Ling Li , Tong Zhang , Bing Wang , Yongzhuo Huang . Phospholipid complex-based microemulsion for treating concurrence of primary sclerosing cholangitis and inflammatory bowel disease via gut-liver crosstalk. Chinese Chemical Letters, 2025, 36(10): 110778-. doi: 10.1016/j.cclet.2024.110778
8. [8]
  Yanfei Liu , Yaqin Hu , Yifu Tan , Qiwen Chen , Zhenbao Liu . Tumor acidic microenvironment activatable DNA nanostructure for precise cancer cell targeting and inhibition. Chinese Chemical Letters, 2025, 36(1): 110289-. doi: 10.1016/j.cclet.2024.110289
9. [9]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
10. [10]
  Junfei Yang , Ke Wang , Shuxin Sun , Tianqi Pei , Junxiu Li , Xunwei Gong , Cuixia Zheng , Yun Zhang , Qingling Song , Lei Wang . A "spore-like" oral nanodrug delivery platform for precision targeted therapy of inflammatory bowel disease. Chinese Chemical Letters, 2025, 36(3): 110180-. doi: 10.1016/j.cclet.2024.110180
11. [11]
  Zhilong Xie , Guohui Zhang , Ya Meng , Yefei Tong , Jian Deng , Honghui Li , Qingqing Ma , Shisong Han , Wenjun Ni . A natural nano-platform: Advances in drug delivery system with recombinant high-density lipoprotein. Chinese Chemical Letters, 2024, 35(11): 109584-. doi: 10.1016/j.cclet.2024.109584
12. [12]
  Zimo Shen , Tongwei Zhang , Zhiyi Zhu , Zonghao Gong , Qing Feng , Jinyi Yang , Zhen Li , Min Liu , Wei Qi . From Alkaloid to Anticancer Agent: The Transformative Journey of Camptothecin. University Chemistry, 2025, 40(10): 161-165. doi: 10.12461/PKU.DXHX202411027
13. [13]
  Peng Chen , Lijuan Liang , Yufei Zhu , Zhimin Xing , Zhenhua Jia , Teck-Peng Loh . Strategies for constructing seven-membered rings: Applications in natural product synthesis. Chinese Chemical Letters, 2024, 35(6): 109229-. doi: 10.1016/j.cclet.2023.109229
14. [14]
  Han Han , Bi-Te Chen , Jia-Rong Ding , Jin-Ming Si , Tian-Jiao Zhou , Yi Wang , Lei Xing , Hu-Lin Jiang . A PDGFRβ-targeting nanodrill system for pancreatic fibrosis therapy. Chinese Chemical Letters, 2024, 35(10): 109583-. doi: 10.1016/j.cclet.2024.109583
15. [15]
  Bakr Ahmed Taha , Ali J. Addie , Luai Farhan Zghair Kolie , Saba Talib Wahhab , Sinan Adnan Abdulateef , Adawiya J. Haider , Khalid Ibnaouf , Norhana Arsad . Advancements in nanophotonics and smart nanomaterials integrated with artificial intelligence-driven gene editing: A paradigm shift in cancer diagnosis and therapeutic. Chinese Chemical Letters, 2026, 37(4): 111955-. doi: 10.1016/j.cclet.2025.111955
16. [16]
  Jialin Guo , Mingrui Gu , Yahui Chen , Tao Xiong , Yiyang Zhang , Simin Chen , Mingle Li , Xiaoqiang Chen , Xiaojun Peng . Nucleic acid delivery by lipid nanoparticles for organ targeting. Chinese Chemical Letters, 2025, 36(11): 110849-. doi: 10.1016/j.cclet.2025.110849
17. [17]
  Kai Wang , Yun Wang , Lihang Wang , Zhuhai Li , Xi Yu , Xuanhe You , Diwei Wu , Yueming Song , Jiancheng Zeng , Zongke Zhou , Shishu Huang , Yunfeng Lin . Therapeutic siRNA targeting CC chemokine receptor 2 loaded with tetrahedral framework nucleic acid alleviates neuropathic pain by regulating microglial polarization. Chinese Chemical Letters, 2025, 36(3): 109868-. doi: 10.1016/j.cclet.2024.109868
18. [18]
  Xiaoyu Hou , Mingyang Liu , Hu Wu , Nan Wang , Xu Zhao , Xifeng Qin , Xiaomin Su , Hanwei Huang , Zihan Ma , Jiahao Liu , Onder Ergonul , Füsun Can , Wei Liu , Zhiqing Pang , Funan Liu . Differential releasing hydrogel loaded with oncolytic viruses and anti-CAFs drug to enhance oncology therapeutic efficacy. Chinese Chemical Letters, 2025, 36(5): 110106-. doi: 10.1016/j.cclet.2024.110106
19. [19]
  Wen Xiao , Fazhan Wang , Yangzhuo Gu , Xi He , Na Fan , Qian Zheng , Shugang Qin , Zhongshan He , Yuquan Wei , Xiangrong Song . PEG400-mediated nanocarriers improve the delivery and therapeutic efficiency of mRNA tumor vaccines. Chinese Chemical Letters, 2024, 35(5): 108755-. doi: 10.1016/j.cclet.2023.108755
20. [20]
  Lu-Lu He , Lan-Tu Xiong , Xin Wang , Yu-Zhen Li , Jia-Bao Li , Yu Shi , Xin Deng , Zi-Ning Cui . Application of inhibitors targeting the type III secretion system in phytopathogenic bacteria. Chinese Chemical Letters, 2025, 36(4): 110044-. doi: 10.1016/j.cclet.2024.110044

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(19)
HTML views(5)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142